

WESTERN SYDNEY UNIVERSITY



Nanoscale Organisation
and Dynamics Group

The Rarest Drug on Earth: Development of Targeted Alpha Therapies

Simon Puttick

simon.puttick@csiro.au
CSIRO

Abstract

Radioisotope therapy has been employed in the treatment of cancer for over 100 years and, for the large part, has remained a very small and niche corner of oncology. Recent developments in peptide-based targeting ligands, radiometal chelators, PET imaging and isotope production methods have driven the development of targeted radioisotope therapy which is gaining increasing clinical interest. In this talk I will describe recent progress in targeted radioisotope therapy, with a particular focus of targeted alpha therapy, and will give an overview of CSIRO's research programs in isotope production and targeting ligand development.

Profile

Dr Puttick completed Ph.D. studies at The University of Nottingham in 2012 under the guidance of Prof Peter Licence after which he briefly joined the Wolfson Brain Imaging Centre at The University of Cambridge as a postdoctoral research fellow. In 2013 he moved to The University of Queensland as a postdoctoral research fellow under the guidance of Prof Stephen Rose to develop new targeted radioisotope therapies for primary brain cancers. In 2016 Dr Puttick was the recipient of a research fellowship jointly awarded by The University of Queensland and CSIRO and in 2018 he moved to CSIRO as a Senior Research Scientist to lead a program of research in targeted radioisotope therapy.

Staff and students at all levels are welcome to attend.

Venue and Time:

This talk will be held on Thursday 12 November at 2 pm via **ZOOM**

Meeting URL: <https://uws.zoom.us/j/82562323854?>

Meeting ID: 825 6232 3854

Password: 898385

Enquiries:

Prof. William S. Price

Ext. 0404 830 398

e-mail: w.price@westernsydney.edu.au